Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | PTPRC | P08575 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | IDO1 | P14902 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | BCHE | P06276 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 2/20 | 0.70 |
| ▸ | CES1 | P23141 | 2/20 | 0.70 |
| ▸ | RECQL | P46063 | 2/20 | 0.70 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2-Naphthoquinone SCHEMBL15167712 | 0.82 | PTPRC (1.00) | PTPN1MEN1KMT2APTPRCMAPT | |
| 1,2-Naphthoquinone SCHEMBL173316 | 0.82 | PTPRC (1.00) | PTPN1MEN1KMT2APTPRCMAPT | |
| 1,2-Naphthoquinone SCHEMBL29363665 | 0.82 | PTPRC (1.00) | PTPN1MEN1KMT2APTPRCMAPT | |
| 1,2-Naphthoquinone SCHEMBL30715501 | 0.80 | PTPRC (0.95) | PTPN1MEN1KMT2APTPRCMAPT | |
| 1,2-Naphthoquinone SCHEMBL30697786 | 0.80 | PTPRC (0.95) | PTPN1MEN1KMT2APTPRCMAPT | |
| 1,2-Naphthoquinone SCHEMBL9245768 | 0.78 | PTPRC (0.91) | PTPN1MEN1KMT2APTPRCMAPT | |
| 9,10-Phenanthrenequinone SCHEMBL19809110 | 0.77 | PTPRC (0.87) | PTPN1MEN1KMT2APTPRCMAPT | |
| 1,2-Naphthoquinone SCHEMBL7746067 | 0.77 | PTPRC (0.87) | PTPN1MEN1KMT2APTPRCMAPT | |
| 1,2-Naphthoquinone SCHEMBL28601611 | 0.77 | PTPRC (0.87) | PTPN1MEN1KMT2APTPRCMAPT | |
| 1,2-Naphthoquinone SCHEMBL20212026 | 0.75 | PTPRC (0.83) | PTPN1MEN1KMT2APTPRCMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2140868-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy | Eisai R&D Management Co., Ltd. (JP) | 2010-01-06 | — | — | EP | claimed |
| EP-2138177-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2009-12-30 | — | — | EP | claimed |
| EP-2133078-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2009-12-16 | — | — | EP | claimed |
| EP-2130538-A1 | Use of a cholinesterase inhibitor for the delaying the onset of Alzheimer's disease | Eisai R&D Management Co., Ltd. (JP) | 2009-12-09 | — | — | EP | claimed |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2008-12-18 | — | — | US | claimed |
| EP-1729761-A4 | CADASIL TREATMENT WITH CHOLINESTERASE INHIBITORS | EISAI CO LTD (JP) | 2008-09-03 | — | — | EP | claimed |
| US-20080045500-A1 | Nerve Regeneration Stimulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-02-21 | — | — | US | claimed |
| EP-1779867-A1 | NERVE REVENERATION PROMOTER | Eisai R&D Management Co., Ltd. (JP) | 2007-05-02 | — | — | EP | claimed |
| EP-1764101-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2007-03-21 | — | — | EP | claimed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| CN-1328451-A | Medicine for improving excretion capacity of bladder | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-26 | — | — | CN | claimed |
| WO-2001066114-A1 | NOVEL METHODS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2001-09-13 | — | — | WO | claimed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | claimed |
| EP-1116716-A1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | Eisai Co., Ltd. (JP) | 2001-07-18 | — | — | EP | claimed |
| EP-0742207-A1 | 2-(Indan-1-one-2-yl-alkyl)-1-phenylalkyl-piperidines and processes for their preparation | Eisai Co., Ltd. (JP) | 1996-11-13 | — | — | EP | claimed |
| EP-0673927-A1 | 4-[2-indanyl-1-one]alkylpiperidines as anticholinergic agents | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | claimed |
| US-5100901-A | Treatment of Alzheimer*s disease | EISAI CO., LTD. (JP) | 1992-03-31 | — | — | US | claimed |
| EP-0296560-A2 | 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease | Eisai Co., Ltd. (JP) | 1988-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | PTPN1 4423/4885MEN1 3739/4885KMT2A 2509/4885 |
| US-20080045500-A1 | Nerve Regeneration Stimulator | ACHE, NGF, GAP43 | PTPN1 3825/4885MEN1 3831/4885KMT2A 3031/4885 |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | NOTCH3, NOTCH2, NOTCH4 | PTPN1 4612/4885MEN1 927/4885KMT2A 140/4885 |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | PTPN1 3986/4885MEN1 571/4885KMT2A 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.